A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain on average 60% of their lost weight – but beyond this, their weight… read more.
A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia…. read more.
When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new Cornell University research, the medications are associated… read more.
Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers. A new study has… read more.
Novo Nordisk presented the full results from STRIDE, a phase III peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic (semaglutide 1.0 mg) in… read more.
Novo Nordisk announced that the FDA has approved Ozempic (semaglutide injection) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to… read more.
A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat… read more.
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such as Wegovy and Ozempic. The survey was conducted by Morning Consult… read more.
Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is… read more.
A study carried out in St Vincent’s University Hospital (SVUH) Dublin challenges the belief that weight loss medications such as Ozempic, Wegovy or Monjaro work just by promoting… read more.
A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with… read more.
The European Medicines Agency (EMA) is warning patients and healthcare professionals to beware of pre-filled pens falsely labelled as Ozempic, a diabetes medicine linked to weight loss. National… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
